It has been shown in a mouse model of melanoma that treatment with anti-CTLA-4 antibody or interleukin 2 (IL-2) immunotherapy leads to persistent production of intratumoral tumor necrosis factor alpha (TNF-α) and T cell accumulation, which increases EZH2 expression (Zingg et al., 2017). Here, TNF is linked to melanoma.